| CAS NO: | 2113650-05-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Molecular Weight | 677.57 |
|---|---|
| Formula | C36H34Cl2N2O7 |
| CAS No. | 2113650-05-6 (HCl) |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 10mM |
| Water: N/A | |
| Ethanol: N/A | |
| Chemical Name | (2R,4R)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)-4-hydroxypyrrolidine-2-carboxylic acid hydrochloride |
| Synonyms | BMS-1166 HCl; BMS 1166; BMS1166 hydrochloride |
| SMILES Code | O=C([C@@H]1N(CC2=CC(Cl)=C(OCC3=CC=CC(C4=CC=C5OCCOC5=C4)=C3C)C=C2OCC6=CC=CC(C#N)=C6)C[C@H](O)C1)O.[H]Cl |
| In Vitro | In vitro activity: BMS-1001 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 protein protein interaction with IC50 value of 2.25 nM in cell free assays. Kinase Assay: BMS disclosed recently the first nonpeptidic small molecule inhibitors against the PD-1/PD-L1 pathway that showed the activity in a homogeneous time-resolved fluorescence (HTRF) binding assay; however no further data supporting their activity were provided. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References |
m.cnreagent.com